"id": "NCT06119581",
    "title": "SUNRAY-01, A Global Pivotal Study in Participants With KRAS G12C-Mutant, Locally Advanced or Metastatic Non-Small Cell Lung Cancer Comparing First-Line Treatment of LY3537982 and Pembrolizumab vs Placebo and Pembrolizumab in Those With PD-L1 Expression ≥50% or LY3537982 and Pembrolizumab, Pemetrexed, Platinum vs Placebo and Pembrolizumab, Pemetrexed, Platinum Regardless of PD-L1 Expression",
    "phase": "PHASE3",
    "description": "No description provided.",
    "inclusion_criteria": [
      "Inclusion Criteria:",
      "",
      "* Histologically or cytologically confirmed NSCLC with Stage IIIB-IIIC or Stage IV disease, not suitable for curative intent radical surgery or radiation therapy.",
      "* Part B and Safety Lead-In Part B: the histology of the tumor must be predominantly non-squamous (in line with pemetrexed label).",
      "* Must have disease with evidence of KRAS G12C mutation.",
      "* Must have known programmed death-ligand 1 (PD-L1) expression",
      "",
      "  * Part A: Greater than or equal to (≥)50 percent (%).",
      "  * Part B: 0% to 100%.",
      "* Must have measurable disease per RECIST v1.1.",
      "* Must have an ECOG performance status of 0 or 1.",
      "* Estimated life expectancy ≥12 weeks.",
      "* Ability to swallow capsules.",
      "* Must have adequate laboratory parameters.",
      "* Contraceptive use should be consistent with local regulations for those participating in clinical studies.",
      "* Women of childbearing potential must",
      "",
      "  * Have a negative pregnancy test.",
      "  * Not be breastfeeding during treatment",
      ""
    ],
    "exclusion_criteria": [

      "Exclusion Criteria:",
      "",
      "* Have a documented additional validated targetable oncogenic driver mutation or alteration in genes such as epidermal growth factor receptor (EGFR), anaplastic lymphoma kinase (ALK), BRAF (V600E), human epidermal growth factor receptor 2 (HER2), MET (exon 14), ROS1, rearranged during transfection (RET), or neurotrophic tyrosine receptor kinase (NTRK)1/2/3.",
      "* Have had any of the following prior to randomization:",
      "",
      "  -- Prior systemic therapy (chemotherapy, immunotherapy, targeted therapy, or biological therapy) for advanced or metastatic NSCLC.",
      "",
      "  --- 1 cycle of standard-of-care treatment prior to study enrollment will be allowed for cases where immediate treatment is clinically indicated:",
      "* Have known active central nervous system metastases and/or carcinomatous meningitis.",
      "",
      "Exclusion Criteria for Participants receiving Pemetrexed and Platinum (Part B and Safety Lead-In Part B)",
      "",
      "* Have predominantly squamous cell histology for NSCLC",
      "* Is unable to interrupt aspirin or other nonsteroidal anti-inflammatory drugs (NSAIDs)",
      "* Is unable or unwilling to take folic acid or vitamin B12 supplementation."
    ],
    "gender": "All",
    "min_age": "18 Years",
    "max_age": "Not specified",
    "status": "RECRUITING",
    "start_date": "2023-12-21",
    "completion_date": "2029-10",
    "sponsor": "Unknown",
    "last_updated": "2025-05-07"
